Skip to main content

Atea Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

AVIR$4.41+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

March 31,2024December 31,2023
Assets
Current assets
Cash and cash equivalents$160,910$143,823
Marketable securities380,581434,283
Prepaid expenses and other current assets7,27312,349
Total current assets548,764590,455
Property and equipment, net1,1851,289
Other assets1,3961,396
Operating lease right-of-use assets, net1,6841,828
Total assets$553,029$594,968
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable$21,137$4,252
Accrued expenses and other current liabilities19,40527,364
Current portion of operating lease liabilities769760
Total current liabilities41,31132,376
Operating lease liabilities1,4451,642
Income taxes payable5,9025,758
Total liabilities48,65839,776
Commitments and contingencies (see Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding——
Common stock, $0.001 par value; 300,000,000 shares authorized; 84,223,100 and 83,435,513 shares issued and outstandingas of March 31, 2024 and December 31, 2023, respectively8483
Additional paid-in capital763,472750,737
Accumulated other comprehensive gain (loss)(181)207
Accumulated deficit(259,004)(195,835)
Total stockholders’ equity504,371555,192
Total liabilities and stockholders’ equity$553,029$594,968
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.